These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis. Raz-Pasteur A, Shasha D, Paul M. Int J Antimicrob Agents; 2015 Sep; 46(3):242-8. PubMed ID: 26092096 [Abstract] [Full Text] [Related]
5. Antibiotic treatment strategies for community-acquired pneumonia in adults. Postma DF, van Werkhoven CH, van Elden LJ, Thijsen SF, Hoepelman AI, Kluytmans JA, Boersma WG, Compaijen CJ, van der Wall E, Prins JM, Oosterheert JJ, Bonten MJ, CAP-START Study Group. N Engl J Med; 2015 Apr 02; 372(14):1312-23. PubMed ID: 25830421 [Abstract] [Full Text] [Related]
6. Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia. Ambroggio L, Taylor JA, Tabb LP, Newschaffer CJ, Evans AA, Shah SS. J Pediatr; 2012 Dec 02; 161(6):1097-103. PubMed ID: 22901738 [Abstract] [Full Text] [Related]
7. Effect of β-Lactam Plus Macrolide Versus Fluoroquinolone on 30-Day Readmissions for Community-Acquired Pneumonia. Gilbert TT, Arfstrom RJ, Mihalovic SW, Dababneh AS, Varatharaj Palraj BR, Dierkhising RA, Mara KC, Lessard SR. Am J Ther; 2020 Dec 02; 27(2):e177-e182. PubMed ID: 30418221 [Abstract] [Full Text] [Related]
8. Antibiotic treatment of moderate-severe community-acquired pneumonia: design and rationale of a multicentre cluster-randomised cross-over trial. van Werkhoven CH, Postma DF, Oosterheert JJ, Bonten MJ. Neth J Med; 2014 Apr 02; 72(3):170-8. PubMed ID: 24846935 [Abstract] [Full Text] [Related]
9. Respiratory fluoroquinolone monotherapy vs. β-lactam plus macrolide combination therapy for hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials. Choi SH, Cesar A, Snow TAC, Saleem N, Arulkumaran N, Singer M. Int J Antimicrob Agents; 2023 Sep 02; 62(3):106905. PubMed ID: 37385561 [Abstract] [Full Text] [Related]
10. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. Garin N, Genné D, Carballo S, Chuard C, Eich G, Hugli O, Lamy O, Nendaz M, Petignat PA, Perneger T, Rutschmann O, Seravalli L, Harbarth S, Perrier A. JAMA Intern Med; 2014 Dec 02; 174(12):1894-901. PubMed ID: 25286173 [Abstract] [Full Text] [Related]
11. The science of selecting antimicrobials for community-acquired pneumonia (CAP). File TM. J Manag Care Pharm; 2009 Mar 02; 15(2 Suppl):S5-11. PubMed ID: 19236135 [Abstract] [Full Text] [Related]
12. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission. Reyes Calzada S, Martínez Tomas R, Cremades Romero MJ, Martínez Moragón E, Soler Cataluña JJ, Menéndez Villanueva R. Respir Med; 2007 Sep 02; 101(9):1909-15. PubMed ID: 17628462 [Abstract] [Full Text] [Related]
13. Impact of guideline-concordant antibiotics and macrolide/β-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study. Asadi L, Eurich DT, Gamble JM, Minhas-Sandhu JK, Marrie TJ, Majumdar SR. Clin Microbiol Infect; 2013 Mar 02; 19(3):257-64. PubMed ID: 22404691 [Abstract] [Full Text] [Related]
14. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. Crit Care; 2005 Dec 06; 10(1):R8. PubMed ID: 16420641 [Abstract] [Full Text] [Related]
15. Effectiveness of β-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With Pneumonia. Williams DJ, Edwards KM, Self WH, Zhu Y, Arnold SR, McCullers JA, Ampofo K, Pavia AT, Anderson EJ, Hicks LA, Bramley AM, Jain S, Grijalva CG. JAMA Pediatr; 2017 Dec 01; 171(12):1184-1191. PubMed ID: 29084336 [Abstract] [Full Text] [Related]
16. Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia. Wilson BZ, Anzueto A, Restrepo MI, Pugh MJ, Mortensen EM. Crit Care Med; 2012 Aug 01; 40(8):2310-4. PubMed ID: 22622401 [Abstract] [Full Text] [Related]
17. Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia. Teh B, Grayson ML, Johnson PD, Charles PG. Clin Microbiol Infect; 2012 Apr 01; 18(4):E71-3. PubMed ID: 22284533 [Abstract] [Full Text] [Related]
18. Is β-Lactam Plus Macrolide More Effective than β-Lactam Plus Fluoroquinolone among Patients with Severe Community-Acquired Pneumonia?: a Systemic Review and Meta-Analysis. Lee JH, Kim HJ, Kim YH. J Korean Med Sci; 2017 Jan 01; 32(1):77-84. PubMed ID: 27914135 [Abstract] [Full Text] [Related]
19. Antibiotic treatment outcomes in community-acquired pneumonia. Çilli A, Sayıner A, Çelenk B, Şakar Coşkun A, Kılınç O, Hazar A, Aktaş Samur A, Taşbakan S, Waterer GW, Havlucu Y, Kılıç Ö, Tokgöz F, Bilge U. Turk J Med Sci; 2018 Aug 16; 48(4):730-736. PubMed ID: 30119147 [Abstract] [Full Text] [Related]
20. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial. Postma DF, Spitoni C, van Werkhoven CH, van Elden LJR, Oosterheert JJ, Bonten MJM. BMC Infect Dis; 2019 Jan 07; 19(1):17. PubMed ID: 30612559 [Abstract] [Full Text] [Related] Page: [Next] [New Search]